PMID- 12637255
OWN - NLM
STAT- MEDLINE
DCOM- 20030718
LR  - 20220310
IS  - 0193-1849 (Print)
IS  - 0193-1849 (Linking)
VI  - 285
IP  - 1
DP  - 2003 Jul
TI  - Androgen therapy improves muscle mass and strength but not muscle quality: 
      results from two studies.
PG  - E16-24
AB  - The relationship of strength to muscle area was used to assess change in muscle 
      quality after anabolic interventions. Study 1: asymptomatic human 
      immunodeficiency virus-positive men (39 +/- 9 yr) were randomized to nandrolone 
      (600 mg/wk) +/- resistance training (RT). Study 2: older healthy men (72 +/- 5 
      yr) were randomized to oxandrolone (20 mg/day) or placebo. Maximum voluntary 
      strength was determined by the 1-repetition maximum (1-RM) method for leg press, 
      flexion and extension, and cross-sectional area of leg muscles by MRI. From study 
      week 0 to study week 12, muscle quality was unchanged with nandrolone, 
      oxandrolone, or oxandrolone placebo, respectively, for total thigh muscles (1.23 
      +/- 0.012 vs. 1.27 +/- 0.29 kg/cm2; 9.0 +/- 1.1 vs. 8.9 +/- 1.2 N/cm2; 8.9 +/- 
      1.2 vs. 8.9 +/- 1.9 N/cm2) and hamstrings (0.41 +/- 0.08 vs. 0.43 +/- 0.07 
      kg/cm2; 0.90 +/- 0.14 vs. 0.95 +/- 0.016 N/cm2; 0.94 +/- 0.23 vs. 0.93 +/- 0.21 
      N/cm2). Lower-extremity 1-RM strength increased several times greater with 
      RT+nandrolone (51-63% increases) than with nandrolone alone (4.7-16%), despite 
      similar increases in muscle area; therefore, muscle quality increased from 1.13 
      +/- 0.17 to 1.51 +/- 0.18 kg/cm2 (+36 +/- 19%; P < 0.001) for total thigh muscle, 
      0.37 +/- 0.10 to 0.53 +/- 0.08 kg/cm2 (+49 +/- 39%; P < 0.001) for hamstrings, 
      and 0.73 +/- 0.19 to 1.07 +/- 0.16 kg/cm2 (+55 +/- 36%; P < 0.001) for 
      quadriceps. Thus androgen therapy alone did not improve muscle quality, but the 
      addition of RT to nandrolone produced substantive improvements.
FAU - Schroeder, E Todd
AU  - Schroeder ET
AD  - Division of Infectious Diseases, Department of Medicine, Keck School of Medicine, 
      University of Southern California, Los Angeles 90033, USA.
FAU - Terk, Michael
AU  - Terk M
FAU - Sattler, Fred R
AU  - Sattler FR
LA  - eng
GR  - DK-49308/DK/NIDDK NIH HHS/United States
GR  - M01 RR-43/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20030311
PL  - United States
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
RN  - 0 (Anabolic Agents)
RN  - 0 (Androgens)
RN  - 6PG9VR430D (Nandrolone)
RN  - 7H6TM3CT4L (Oxandrolone)
RN  - H45187T098 (Nandrolone Decanoate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anabolic Agents/adverse effects/therapeutic use
MH  - Androgens/adverse effects/*therapeutic use
MH  - Body Composition/drug effects
MH  - HIV Seropositivity/pathology
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*drug effects/growth & development/*physiology
MH  - Nandrolone/adverse effects/*analogs & derivatives/therapeutic use
MH  - Nandrolone Decanoate
MH  - Organ Size/drug effects
MH  - Oxandrolone/adverse effects/therapeutic use
MH  - Physical Fitness
MH  - Prospective Studies
EDAT- 2003/03/15 04:00
MHDA- 2003/07/19 05:00
CRDT- 2003/03/15 04:00
PHST- 2003/03/15 04:00 [pubmed]
PHST- 2003/07/19 05:00 [medline]
PHST- 2003/03/15 04:00 [entrez]
AID - 00032.2003 [pii]
AID - 10.1152/ajpendo.00032.2003 [doi]
PST - ppublish
SO  - Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E16-24. doi: 
      10.1152/ajpendo.00032.2003. Epub 2003 Mar 11.